Antigen-independent tumor targeting by CBX-12 (alphalex™–exatecan) induces long-term antitumor immunity
Gayle S, Paradis T, Jones K, Vasquez J, Paralkar V. Antigen-independent tumor targeting by CBX-12 (alphalex™–exatecan) induces long-term antitumor immunity. Immunotherapy 2022, 14: 1467-1480. PMID: 36597724, DOI: 10.2217/imt-2022-0121.Peer-Reviewed Original ResearchConceptsLong-term antitumor immunityAntitumor immunityImmune recognition of tumor cellsInducer of immunogenic cell deathRecognition of tumor cellsAnti-PD-1Immunogenic cell deathDelayed tumor growthExpression of MHC-1Immunotherapy combinationsPH-sensitive peptidesComplete responseCT26 modelPD-L1Tumor cellsTumor targetingTumor growthCured animalsClinical trialsELISA assayImmunotherapyMHC-1Cell deathFunctional assaysImmunity